Purpose : Growth impairment is well known to occur in children with congenital heart disease (CHD). However, studies of final height and weight have been insufficient in this population. The aim of this study was to evaluate the final growth of children with CHD and to identify the relationship between CHD and final growth. Methods : We studied CHD patients over 19 years of age who visited Chonnam National University Hospital (CNUH) between November 2000 and March 2009. Patients with comorbidities influencing final height and weight were excluded from the study. Final height and weight were determined for those of over 19year of age and we reviewed the medical data. Final growth of children with CHD were compared with the Korean standard growth level. Enrolled patients were subdivided in different groups: acyanotic versus cyanotic heart disease, type of disease, age at diagnosis, operative group versus non-operative group, and age at surgery. The growths of the groups were compared. Results : Our study included 105 patients: 58 males and 47 females. The mean height and weight in the male group were 170.9± 7.5 cm and 62.7± 11.3 kg. The mean height and weight in the female group were 159.4± 6.4 cm, and 52.2± 7.8 kg. The mean weight and height of male patients with CHD were significantly lower than those of the standard growth curve. Patients with severe growth impairment (below the third percentile of normal) included 5 males (8.6%) and 4 females (8.5%) with regard to height and 9 males (15.5%) and 8 females (17.0%) with regard to weight. The cyanotic heart disease group showed lower mean growth, but a statistically significant difference existed only in male weight. In a comparative study looking at the type of CHD, a significant difference was noted in male weight. Patients with patent ductus arteriosus had the highest mean value of weight, and those with tetralogy of Fallot had the lowest mean value. Conclusions : Impaired final growth was seen in male patients with CHD compared to normal children. Every effort should be taken to treat patients during the optimal time window. Hence, attentive observation of CHD is necessary, and if growth impairment is detected through regular follow-up, treatment is recommended.